Skip to main content

Advertisement

Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Page 2 of 6

  1. Content type: Case report

    The presence of circulating anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) has been described in sera of patients with different inflammatory conditions of the central nervous system. In adults ...

    Authors: Sara Mariotto, Salvatore Monaco, Patrick Peschl, Ilaria Coledan, Romualdo Mazzi, Romana Höftberger, Markus Reindl and Sergio Ferrari

    Citation: BMC Neurology 2017 17:190

    Published on:

  2. Content type: Research article

    In recent years, shared decision making (SDM) has been promoted as a model to guide interactions between persons with MS and their neurologists to reach mutually satisfying decisions about disease management –...

    Authors: S. Michelle Driedger, Ryan Maier, Ruth Ann Marrie and Melissa Brouwers

    Citation: BMC Neurology 2017 17:176

    Published on:

  3. Content type: Research article

    Maintaining patient adherence to disease modifying drugs in multiple sclerosis is a challenge, which can be improved by autoinjectors. The BETACONNECT® is a fully electronic autoinjector for the injection of i...

    Authors: Ingo Kleiter, Michael Lang, Judith Jeske, Christiane Norenberg, Barbara Stollfuß and Markus Schürks

    Citation: BMC Neurology 2017 17:174

    Published on:

  4. Content type: Research article

    The cerebral subcortical deep gray matter nuclei (DGM) are a common, early, and clinically-relevant site of atrophy in multiple sclerosis (MS). Robust and reliable DGM segmentation could prove useful to evalua...

    Authors: Renxin Chu, Shelley Hurwitz, Shahamat Tauhid and Rohit Bakshi

    Citation: BMC Neurology 2017 17:172

    Published on:

  5. Content type: Research article

    Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β...

    Authors: Chiara Zecca, Giulio Disanto, Sarah Mühl and Claudio Gobbi

    Citation: BMC Neurology 2017 17:171

    Published on:

  6. Content type: Research article

    Multiple sclerosis (MS) is a demyelinating disease with a wide range of symptoms including walking impairment and neuropathic pain mainly represented by mechanical allodynia. Noteworthy, exercise preconditioni...

    Authors: Danielle Bernardes and Alexandre Leite Rodrigues Oliveira

    Citation: BMC Neurology 2017 17:160

    Published on:

  7. Content type: Research article

    Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-ef...

    Authors: Frank A. Hoffmann, Anastasiya Trenova, Miguel A. Llaneza, Johannes Fischer, Giacomo Lus, Dorothea von Bredow, Núria Lara, Elaine Lam, Marlies Van Hoef and Rajesh Bakshi

    Citation: BMC Neurology 2017 17:156

    Published on:

  8. Content type: Research article

    The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant...

    Authors: Paolo Ragonese, Paolo Aridon, Giulia Vazzoler, Maria Antonietta Mazzola, Vincenzina Lo Re, Marianna Lo Re, Sabrina Realmuto, Simona Alessi, Marco D’Amelio, Giovanni Savettieri and Giuseppe Salemi

    Citation: BMC Neurology 2017 17:155

    Published on:

  9. Content type: Research article

    In multiple sclerosis (MS), neurological disability results from incomplete remission of relapses and from relapse-independent progression. Intravenous high dose methylprednisolone (IVMP) is the established st...

    Authors: Muriel Stoppe, Maria Busch, Luise Krizek and Florian Then Bergh

    Citation: BMC Neurology 2017 17:151

    Published on:

  10. Content type: Research article

    Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse. The Prospective Evaluation...

    Authors: Anat Achiron, Hany Aref, Jihad Inshasi, Mohamad Harb, Raed Alroughani, Mahendra Bijarnia, Kathryn Cooke and Ozgur Yuksel

    Citation: BMC Neurology 2017 17:150

    Published on:

  11. Content type: Research article

    Clinically isolated syndrome (CIS) represents first neurological symptoms suggestive of demyelinating lesion in the central nervous system (CNS). Currently, there are no sufficient immunological or genetic mar...

    Authors: Helena Posová, Dana Horáková, Václav Čapek, Tomáš Uher, Zdenka Hrušková and Eva Havrdová

    Citation: BMC Neurology 2017 17:145

    Published on:

  12. Content type: Research article

    Post-traumatic Guillain-Barré syndrome (GBS) is a rarely described potentially life-threatening cause of weakness. We sought to elucidate the clinical features and electrophysiological patterns of post-traumat...

    Authors: Xiaowen Li, Jinting Xiao, Yanan Ding, Jing Xu, Chuanxia Li, Yating He, Hui Zhai, Bingdi Xie and Junwei Hao

    Citation: BMC Neurology 2017 17:142

    Published on:

  13. Content type: Research article

    The impact of comorbidity on multiple sclerosis (MS) is a new area of interest. Limited data on the risk factors of metabolic syndrome (MetS) is currently available. The aim of this study was to estimate the p...

    Authors: Antoni Sicras-Mainar, Elena Ruíz-Beato, Ruth Navarro-Artieda and Jorge Maurino

    Citation: BMC Neurology 2017 17:134

    Published on:

  14. Content type: Research article

    Neuromyelitis optica spectrum disorders (NMOSD) are demyelinating autoimmune diseases in the central nervous system (CNS) that are characterized by a high relapse rate and the presence of anti-aquaporin 4 anti...

    Authors: Xindi Li, Shenghui Mei, Xiaoqing Gong, Heng Zhou, Li Yang, Anna Zhou, Yonghong Liu, Xingang Li, Zhigang Zhao and Xinghu Zhang

    Citation: BMC Neurology 2017 17:130

    Published on:

  15. Content type: Case report

    Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disorder characterized by multiple affected systems. More than half of SLE patients will suffer from neuropsychiatric lupus erythematosus (NPSLE...

    Authors: Bolin Hu, Pengcheng Wu, Yibiao Zhou, Yan Peng, Xiaoping Tang, Weijiang Ding, Ming Zhang and Xueliang Qi

    Citation: BMC Neurology 2017 17:123

    Published on:

  16. Content type: Research article

    Recent exercise guidelines for people with multiple sclerosis (MS) recommend a minimum of 30 min moderate intensity aerobic exercise and resistance exercise twice per week. This trial compared the secondary ou...

    Authors: Susan Coote, Marcin Uszynski, Matthew P. Herring, Sara Hayes, Carl Scarrott, John Newell, Stephen Gallagher, Aidan Larkin and Robert W Motl

    Citation: BMC Neurology 2017 17:119

    Published on:

  17. Content type: Research article

    Administrative healthcare claims data provide a mechanism for assessing and monitoring multiple sclerosis (MS) disease status across large, clinically representative “real-world” populations. The estimation of...

    Authors: Michael Munsell, Molly Frean, Joseph Menzin and Amy L. Phillips

    Citation: BMC Neurology 2017 17:106

    Published on:

  18. Content type: Case Report

    Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) is a rare clinico-radiological entity characterized by the magnetic resonance imaging (MRI) finding of a reversible lesion in the corpus ...

    Authors: Junliang Yuan, Shuna Yang, Shuangkun Wang, Wei Qin, Lei Yang and Wenli Hu

    Citation: BMC Neurology 2017 17:103

    Published on:

  19. Content type: Research article

    Multiple sclerosis (MS) is a stressful condition. Mental health comorbidity is common. Stress can increase the risk of depression, reduce quality of life (QOL), and possibly exacerbate disease activity in MS. ...

    Authors: Robert Simpson, Frances S. Mair and Stewart W. Mercer

    Citation: BMC Neurology 2017 17:94

    Published on:

  20. Content type: Research article

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is presented by a large heterogeneity of clinical phenotypes. Around 50% of patients suffer from typical CIDP and show better therapy response than atyp...

    Authors: M. Staudt, J. M. Diederich, C. Meisel, A. Meisel and J. Klehmet

    Citation: BMC Neurology 2017 17:81

    Published on:

  21. Content type: Case report

    Anti-Myelin oligodendrocyte glycoprotein (MOG) antibodies are detected in various demyelinating diseases, such as pediatric acute disseminated encephalomyelitis (ADEM), recurrent optic neuritis, and aquaporin-...

    Authors: Yoshitsugu Nakamura, Hideto Nakajima, Hiroki Tani, Takafumi Hosokawa, Shimon Ishida, Fumiharu Kimura, Kimihiko Kaneko, Toshiyuki Takahashi and Ichiro Nakashima

    Citation: BMC Neurology 2017 17:76

    Published on:

  22. Content type: Research article

    People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression a...

    Authors: Trygve Holmøy, Jonas Christoffer Lindstrøm, Erik Fink Eriksen, Linn Hofsøy Steffensen and Margitta T. Kampman

    Citation: BMC Neurology 2017 17:67

    Published on:

  23. Content type: Case report

    The mortality of septicaemia, meningitis and encephalitis caused by Listeria monocytogenes is 20–40%. Twenty-one cases of invasive listeriosis associated with alemtuzumab, including at least 16 in patients with m...

    Authors: Trygve Holmøy, Hedda von der Lippe and Truls Michael Leegaard

    Citation: BMC Neurology 2017 17:65

    Published on:

  24. Content type: Study protocol

    Nocturia (the symptom of needing to wake up to pass urine) is common in progressive Multiple Sclerosis (MS) patients. Moderate-to-severe nocturia affects quality of life, can exacerbate fatigue and may affect ...

    Authors: D. Delgado, L. Canham, N. Cotterill, D. Cottrell, M. J. Drake, K. Inglis, D. Owen and P. White

    Citation: BMC Neurology 2017 17:63

    Published on:

  25. Content type: Research article

    Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and cos...

    Authors: Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel and Ming-Yi Huang

    Citation: BMC Neurology 2017 17:62

    Published on:

  26. Content type: Research article

    Continuation of interferon (IFN) β-based therapies is important for maximum treatment effectiveness in patients with multiple sclerosis (MS); however, few real-world data are available on discontinuation from ...

    Authors: Meritxell Sabidó-Espin and Rick Munschauer

    Citation: BMC Neurology 2017 17:57

    Published on:

  27. Content type: Research article

    The Multiple Sclerosis Questionnaire for Physical Therapists (MSQPT) is a patient-rated outcome questionnaire for evaluating the rehabilitation of persons with multiple sclerosis (MS). Responsiveness was evalu...

    Authors: Nico Arie van der Maas

    Citation: BMC Neurology 2017 17:50

    Published on:

  28. Content type: Research article

    Despite the high comorbidity of anxiety and depression in people with multiple sclerosis (MS), little is known about their inter-relationships. Both involve emotional perturbations and the way in which emotion...

    Authors: Marie-Claire Gay, Catherine Bungener, Sarah Thomas, Pierre Vrignaud, Peter W Thomas, Roger Baker, Sébastien Montel, Olivier Heinzlef, Caroline Papeix, Rana Assouad and Michèle Montreuil

    Citation: BMC Neurology 2017 17:43

    Published on:

  29. Content type: Case report

    Hashimoto’s encephalitis (HE) is a rare neurological complication of Hashimoto’s thyroiditis (HT), while limbic encephalitis (LE) is an autoimmune inflammatory disorder frequently associated with anti-neuronal...

    Authors: Mingqin Zhu, Xuefan Yu, Caiyun Liu, Chenchen Duan, Chunxiao Li, Jie Zhu and Ying Zhang

    Citation: BMC Neurology 2017 17:37

    Published on:

  30. Content type: Research article

    Subcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense and gadolinium-enhancing (Gd+) lesions over 2 years in patients with relapsing-remitting multiple sclerosis ...

    Authors: Douglas L. Arnold, Peter A. Calabresi, Bernd C. Kieseier, Shifang Liu, Xiaojun You, Damian Fiore and Serena Hung

    Citation: BMC Neurology 2017 17:29

    Published on:

  31. Content type: Research article

    The low level of disease activity and manageable safety profile seen with fingolimod versus placebo in a 6-month, phase 2, randomized controlled trial in Japanese patients with relapsing multiple sclerosis (MS...

    Authors: Takahiko Saida, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kengo Ueda, Lixin Zhang Auberson, Isao Tsumiyama, Kazuo Nagato and Jun-ichi Kira

    Citation: BMC Neurology 2017 17:17

    Published on:

  32. Content type: Case report

    Longitudinally Extensive Transverse Myelitis LETM is a specific pattern of myelitis wherein at least three continuous vertebral segments are involved. Characteristically, it is a defining feature of neuromyeli...

    Authors: Rana Alnasser Alsukhni, Yasmin Aboras, Ziena Jriekh, Mahmoud Almalla and Ahmad Sheikh El-Kahwateya

    Citation: BMC Neurology 2017 17:13

    Published on:

  33. Content type: Research article

    First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose. Individual bradyarrhythmic epis...

    Authors: Volker Limmroth, Tjalf Ziemssen, Michael Lang, Stephan Richter, Bert Wagner, Judith Haas, Stephan Schmidt, Kathrin Gerbershagen, Christoph Lassek, Luisa Klotz, Olaf Hoffmann, Christian Albert, Katrin Schuh, Monika Baier-Ebert, Guillaume Wendt, Heinke Schieb…

    Citation: BMC Neurology 2017 17:11

    Published on:

  34. Content type: Research article

    Physical activity (PA) is frequently restricted in people with multiple sclerosis (PwMS) and aiming to enhance PA is considered beneficial in this population. We here aimed to explore two standard methods (sub...

    Authors: Theresa Krüger, Janina R. Behrens, Anuschka Grobelny, Karen Otte, Sebastian Mansow-Model, Bastian Kayser, Judith Bellmann-Strobl, Alexander U. Brandt, Friedemann Paul and Tanja Schmitz-Hübsch

    Citation: BMC Neurology 2017 17:10

    Published on:

  35. Content type: Case report

    Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a clinically heterogeneous disorder characterized by epileptic seizures, psychosis, dyskinesia, consciousness impairments, and autonomic instability. ...

    Authors: Kaiyu Qin, Wenqing Wu, Yuming Huang, Dongmei Xu, Lei Zhang, Bowen Zheng, Meijuan Jiang, Cheng Kou, Junhua Gao, Wurong Li, Jinglin Zhang, Sumei Wang, Yanfei Luan, Chaoling Yan, Dan Xu and Xinmei Zheng

    Citation: BMC Neurology 2017 17:1

    Published on:

  36. Content type: Research article

    Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this ...

    Authors: Cecilia Smith Simonsen, Elisabeth Gulowsen Celius, Cathrine Brunborg, Chantal Tallaksen, Erik Fink Eriksen, Trygve Holmøy and Stine Marit Moen

    Citation: BMC Neurology 2016 16:252

    Published on:

  37. Content type: Research article

    Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course o...

    Authors: Raed Alroughani, Dirk Deleu, Khalid El Salem, Jasem Al-Hashel, K. John Alexander, Mohamed Assem Abdelrazek, Adel Aljishi, Jaber Alkhaboori, Faisal Al Azri, Nahida Al Zadjali, Majed Hbahbih, Tag Eldin Sokrab, Mohamed Said and Àlex Rovira

    Citation: BMC Neurology 2016 16:240

    Published on:

  38. Content type: Research article

    Health-related quality of life (QOL) is a key outcome for people with multiple sclerosis (MS). While modifiable lifestyle factors, like smoking, physical activity and vitamin D, have strong associations with d...

    Authors: George A Jelinek, Alysha M De Livera, Claudia H Marck, Chelsea R Brown, Sandra L Neate, Keryn L Taylor and Tracey J Weiland

    Citation: BMC Neurology 2016 16:235

    Published on:

  39. Content type: Research article

    Sexual dysfunction (SD) is very common in people with multiple sclerosis (PwMS) and contributes a significant burden of disease, particularly for young people. SD has direct neurological contributions from dep...

    Authors: Claudia H. Marck, Pia L. Jelinek, Tracey J. Weiland, Jane S. Hocking, Alysha M. De Livera, Keryn L. Taylor, Sandra L. Neate, Naresh G. Pereira and George A. Jelinek

    Citation: BMC Neurology 2016 16:210

    Published on:

  40. Content type: Research article

    Recent studies suggest that cortical lesions in multiple sclerosis (MS) substantially contribute to clinical disease severity. The present study aimed at investigating clinical, neuroanatomical, and cognitive ...

    Authors: Olivia Geisseler, Tobias Pflugshaupt, Ladina Bezzola, Katja Reuter, David Weller, Bernhard Schuknecht, Peter Brugger and Michael Linnebank

    Citation: BMC Neurology 2016 16:204

    Published on:

  41. Content type: Research article

    Acute brainstem syndrome (ABS) may herald multiple sclerosis (MS), neuromyelitis optica (NMO), or occur as an isolated syndrome. The aquaporin 4 (AQP4)-specific serum autoantibody, NMO-IgG, is a biomarker for ...

    Authors: Chen Cheng, Ying Jiang, Xiaodong Lu, Fu Gu, Zhuang Kang, Yongqiang Dai, Zhengqi Lu and Xueqiang Hu

    Citation: BMC Neurology 2016 16:203

    Published on:

  42. Content type: Case report

    Leber’s hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding’s disease. Little is known about the response ...

    Authors: Trygve Holmøy, Antonie G. Beiske, Svetozar Zarnovicky, Aija Zuleron Myro, Egil Røsjø and Emilia Kerty

    Citation: BMC Neurology 2016 16:197

    Published on:

  43. Content type: Research article

    In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily dose...

    Authors: Tara Nazareth, Howard S. Friedman, Prakash Navaratnam, Denise A. Herriott, John J. Ko, Peri Barr and Rahul Sasane

    Citation: BMC Neurology 2016 16:187

    Published on:

  44. Content type: Research article

    Since the application of MRI scanning to the diagnosis and treatment of multiple sclerosis, it has been recognized that only a small fraction of lesions seen on MRI scans produce recognizable symptoms or neuro...

    Authors: Stanley Cohan, Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner and Lois Grote

    Citation: BMC Neurology 2016 16:184

    Published on:

  45. Content type: Research article

    Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients’ perception of treatment efficacy. T...

    Authors: Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler and Michael Hecker

    Citation: BMC Neurology 2016 16:181

    Published on:

  46. Content type: Case report

    Guillain-Barré syndrome is an acquired polyradiculo-neuropathy, often preceded by an antecedent event. It is a monophasic disease but a recurrence rate of 1–6 % is documented in a subset group of patients. Pat...

    Authors: Sonali Sihindi Chapa Gunatilake, Rohitha Gamlath and Harith Wimalaratna

    Citation: BMC Neurology 2016 16:161

    Published on: